Imaging studies in movement disorders

Seminars in Nuclear Medicine

Volumn 33, Issue 2, 2003, Pages 105-113

  Seibyl, John P ^a  

^a Inst for Neurodeg Disorders   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3BETA (4 IODOPHENYL) 2BETA TROPANECARBOXYLIC ACID METHYL ESTER; CEP 1347; DOPA; DOPAMINE; DOPAMINE RECEPTOR STIMULATING AGENT; DOPAMINE TRANSPORTER; FLUORINE 18; IMMUNOPHILIN; IODINE 123; NEUROIMMUNOPHILIN A; NEUROPROTECTIVE AGENT; PRAMIPEXOLE; RILUZOLE; ROPINIROLE; UBIDECARENONE; UNCLASSIFIED DRUG;

ARTICLE; BRAIN DEGENERATION; CLINICAL RESEARCH; CLINICAL TRIAL; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; DISEASE COURSE; DOPAMINE BRAIN LEVEL; DOPAMINE RELEASE; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; HUMAN; MOLECULAR BIOLOGY; MOTOR DYSFUNCTION; NERVE DEGENERATION; PARKINSON DISEASE; PATHOPHYSIOLOGY; PATIENT SELECTION; PHASE 2 CLINICAL TRIAL; POSITRON EMISSION TOMOGRAPHY; PRESYNAPTIC POTENTIAL; RELIABILITY; TARGET CELL;

EID: 0037936608     PISSN: 00012998     EISSN: None     Source Type: Journal    
DOI: 10.1053/snuc.2003.127303     Document Type: Article

References (69)

1. Hoehn MM, Yahr MD: Parkinsonism: Onset, progression and mortality. Neurology 17:427-442, 1967
2. Bernheimer H, Birkmayer W, Hornykiewicz O, et al: Brain dopamine and the syndromes of parkinson and huntington. Clinical, morphological and neurochemical correlations. J Neurol Sci. 20:415-455, 1973
3. Brooks DJ: PET and SPECT studies in parkinson's disease. Baillieres Clin Neurol 6:69-87, 1997
4. Mozley PD, Schneider JS, Acton PD, et al: Binding of [99mtc]trodat-1 to dopamine transporters in patients with parkinson's disease and in healthy volunteers. J Nucl Med 41:584-589, 2000
5. Brooks DJ: Morphological and functional imaging studies on the diagnosis and progression of parkinson's disease. J Neurol 247 Suppl 2:1111-18, 2000
6. Marek K, Innis R, van Dyck C, et al: [123-I]beta-CIT SPECT imaging assessment of the rate of parkinson's disease progression. Neurology 57:2089-2094, 2001
7. Seibyl JP, Marek KL, Quinlan D, et al: Decreased single-photon emission computed tomographic [123-I]beta-CIT striatal uptake correlates with symptom severity in parkinson's disease. Ann Neurol 138:589-598, 1995
8. Benamer HT, Patterson J, Wyper DJ, et al: Correlation of parkinson's disease severity and duration with 123I-FP-CIT SPECT striatal uptake. Mov Disord 15:692-698, 2000
9. Fischman AJ, Bonab AA, Babich JW, et al: Rapid detection of parkinson's disease by SPECT with altropane: A selective ligand for dopamine transporters. Synapse 29:128-141, 1998
10. Ichise M, Kim YJ, Ballinger JR, et al: SPECT imaging of pre- and postsynaptic dopaminergic alterations in 1-dopa-untreated PD. Neurology 52:1206-1214, 1999
11. Frey KA, Koeppe RA, Kilbourn MR, et al: Presynaptic monoaminergic vesicles in parkinson's disease and normal aging. Ann Neurol 40:873-884, 1996
12. Brooks DJ: PET studies and motor complications in Parkinson's disease. Trends Neurosci 23:S101-108, 2000
13. Brooks DJ: Positron emission tomography studies in movement disorders. Neurosurg Clin N Am 9:263-282, 1998
14. Morrish PK, Sawle GV, Brooks DJ: The rate of progression of Parkinson's disease. A longitudinal [18F]dopa PET study. Adv Neurol 69:427-431, 1996
15. Nurmi E, Ruottinen HM, Kaasinen V, et al: Progression in Parkinson's disease: A positron emission tomography study with a dopamine transporter ligand [18F]CFT. Ann Neurol 47:804-808, 2000
16. Hall H, Halldin C, Guilloteau D, et al: Visualization of the dopamine transporter in the human brain postmortem with the new selective ligand [125I]PE2i. Neuroimage 9:108-116, 1999
17. Madras BK, Gracz LM, Fahey MA, et al: Altropane, a SPECT or PET imaging probe for dopamine neurons: Iii. Human dopamine transporter in postmortem normal and parkinson's diseased brain. Synapse 29:116-127, 1998
18. Harrington KA, Augood SJ, Kingsbury AE, et al: Dopamine transporter (DAT) and synaptic vesicle amine transporter (VMAT2) gene expression in the substantia nigra of control and Parkinson's disease. Brain Res Mol Brain Res 36:157-162, 1996
19. Ishikawa T, Dhawan V, Kazumata K, et al: Comparative nigrostriatal dopaminergic imaging with iodine-123-beta CIT-FP/SPECT and fluorine-18-fdopa/PET. J Nucl Med 37:1760-1765, 1996
20. Tissingh G, Bergmans P, Winogrodzka A, et al: Nigrostriatal dopaminergic imaging with iodine-123-beta CIT-FP/SPECT and fluorine-18-fdopa/PET. J Nucl Med 38:1271-1272, 1997
21. Ito Y, Fujita M, Shimada S, et al: Comparison between the decrease of dopamine transporter and that of 1-dopa uptake for detection of early to advanced stage of parkinson's disease in animal models. Synapse 31:178-185, 1999
22. Marek K, Seibyl J: Techsight. Imaging. A molecular map for neurodegeneration. Science 289:409-411, 2000
23. Lavalaye J, Booij J, Reneman L, et al: Effect of age and gender on dopamine transporter imaging with [123I]FP-CIT SPECT in healthy volunteers. Eur J Nucl Med 27:867-869, 2000
24. Booij J, Tissingh G, Boer GJ, et al: [1231]FP-CIT SPECT shows a pronounced decline of striatal dopamine transporter labelling in early and advanced Parkinson's disease. J Neurol Neurosurg Psychiatr 62:133-140, 1997
25. van Dyck CH, Seibyl JP, Malison RT, et al: Age-related decline in dopamine transporters: Analysis of striatal subregions, nonlinear effects, and hemispheric asymmetries. Am J Geriatr Psychiatr 10:36-43, 2002
26. Neumeyer JL, Wang SY, Milius RA, et al: [123I]-2 beta-carbomethoxy-3 beta-(4-iodophenyl)tropane: High-affinity SPECT radiotracer of monoamine reuptake sites in brain. J Med Chem 34:3144-3146, 1991
27. Kung MP, Stevenson DA, Plossl K, et al: [99mTc]trodatI: A novel technetium-99m complex as a dopamine transporter imaging agent. Eur J Nucl Med 24:372-380, 1997
28. Madras BK, Gracz LM, Meltzer PC, et al: Altropane, a SPECT or PET imaging probe for dopamine neurons: Ii. Distribution to dopamine-rich regions of primate brain. Synapse 29:105-115, 1998
29. Seibyl JP, Marek K, Sheff K, et al: Iodine-123-beta-CIT and iodine-123-FP-CIT SPECT measurement of dopamine transporters in healthy subjects and Parkinson's patients. J Nucl Med 39:1500-1508, 1998
30. Booij J, Speelman JD, Horstink MW, et al: The clinical benefit of imaging striatal dopamine transporters with [123I]FP-CIT SPET in differentiating patients with presynaptic parkinsonism from those with other forms of parkinsonism. Eur J Nucl Med 28:266-272, 2001
31. Huang WS, Lin SZ, Lin JC, et al: Evaluation of earlystage Parkinson's disease with 99mtc-trodat-1 imaging. J Nucl Med 42:1303-1308, 2001
32. Vander Borght T, Kilbourn M, Desmond T, et al: The vesicular monoamine transporter is not regulated by dopaminergic drug treatments. Eur J Pharmacol 294:577-583, 1995
33. Hughes AJ, Daniel SE, Kilford L, et al: Accuracy of clinical diagnosis of idiopathic parkinson's disease: A clinicopathological study of 100 cases. J Neurol Neurosurg Psychiatr 55:181-184, 1992
34. Hughes AJ, Ben-Shlomo Y, Daniel SE, et al: What features improve the accuracy of clinical diagnosis in Parkinson's disease: A clinicopathologic study. Neurology 57:S34-38, 2001
35. Calne DB: Diagnosis and treatment of Parkinson's disease. Hosp Pract (Off Ed) 30:83-86, 89, 1995
36. Brooks DJ: The early diagnosis of Parkinson's disease. Ann Neurol 44:S10-18, 1998
37. Wolters EC, Francot C, Bergmans P, et al. Preclinical (premotor) Parkinson's disease. J Neurol 247:II103-109, 2000 (Suppl 2)
38. Parkinson's Study Group: A multicenter assessment of dopamine transporter imaging with Dopascan/SPECT in Parkinsonism. Neurology 55:1540-1547, 2000
39. Fernandez HH, Friedman JH, Fischman AJ, et al: Is altropane SPECT more sensitive to fluorodopa PET for detecting early parkinson's disease? Med Sci Monit 7:1339-1343, 2001
40. Marek KL, Seibyl JP, Zoghbi SS, et al: [123I] beta-CIT/SPECT imaging demonstrates bilateral loss of dopamine transporters in hemi-parkinson's disease. Neurology 46:231-237, 1996
41. Staffen W, Mair A, Unterrainer J, et al: [123I] beta-CIT binding and SPET compared with clinical diagnosis in parkinsonism. Nucl Med Commun 21:417-424, 2000
42. Benamer TS, Patterson J, Grosset DG, et al: Accurate differentiation of parkinsonism and essential tremor using visual assessment of [123I]-FP-CIT SPECT imaging: The [123I]-FP-CIT study group. Mov Disord 15:503-510, 2000
43. Tissingh G, Booij J, Bergmans P, et al: Iodine-123-n-omega-fluoropropyl-2beta-carbomethoxy-3beta-(4-iod ophenyl)tropane SPECT in healthy controls and early-stage, drug-naive parkinson's disease. J Nucl Med 39:1143-1148; 1998
44. Brucke T, Asenbaum S, Pirker W, et al: Measurement of the dopaminergic degeneration in parkinson's disease with [123I] beta-CIT and SPECT. Correlation with clinical findings and comparison with multiple system atrophy and progressive supranuclear palsy. J Neural Transm Suppl 50:9-24, 1997
45. Asenbaum S, Pirker W, Angelberger P, et al: [123I]beta-CIT and SPECT in essential tremor and parkinson's disease. J Neural Transm 105:1213-1228, 1998
46. Meara J, Bhowmick BK, Hobson P: Accuracy of diagnosis in patients with presumed parkinson's disease. Age Ageing 28:99-102, 1999
47. Varrone A, Marek KL, Jennings D, et al: [(123)I]beta-CIT SPECT imaging demonstrates reduced density of striatal dopamine transporters in parkinson's disease and multiple system atrophy. Mov Disord 16:1023-1032, 2001
48. Messa C, Volonte MA, Fazio F, et al: Differential distribution of striatal [123I]beta-CIT in parkinson's disease and progressive supranuclear palsy, evaluated with single-photon emission tomography. Eur J Nucl Med 25:1270-1276, 1998
49. Brucke T, Djamshidian S, Bencsits G, et al: SPECT and PET imaging of the dopaminergic system in parkinson's disease. J Neurol 247:IV/2-7, 2000(Suppl 4)
50. Staffen W, Mair A, Unterrainer J, et al: Measuring the progression of idiopathic parkinson's disease with [123I] beta-CIT SPECT. J Neural Transm 107:543-552, 2000
51. Morrish PK, Rakshi JS, Bailey DL, et al: Measuring the rate of progression and estimating the preclinical period of parkinson's disease with [18f]dopa PET. J Neurol Neurosurg Psychiatr 64:314-319, 1998
52. Brooks DJ: Monitoring neuroprotection and restorative therapies in parkinson's disease with PET. J Neural Transm Suppl 125-137, 2000
53. Parkinson study group: A randomized controlled trial comparing pramipexole with levodopa in early parkinson's disease: Design and methods of the CALM-PD study. Clin Neuropharmacol 23:34-44, 2000
54. Parkinson study group: Pramipexole vs levodopa as initial treatment for parkinson disease: A randomized controlled trial. JAMA 284:1931-1938, 2000
55. Kish SJ, Kalasinsky KS, Derkach P, et al: Striatal dopaminergic and serotonergic markers in human heroin users. Neuropsychopharmacology 24:561-567, 2001
56. Volkow ND, Chang L, Wang GJ, et al: Loss of dopamine transporters in methamphetamine abusers recovers with protracted abstinence. J Neurosci 21:9414-9418, 2001
57. Lee CS, Samii A, Sossi V, et al: In vivo positron emission tomographic evidence for compensatory changes in presynaptic dopaminergic nerve terminals in parkinson's disease. Ann Neurol 47:493-503, 2000
58. Donovan DM, Miner LL, Perry MP, et al: Cocaine reward and MPTP toxicity: Alteration by regional variant dopamine transporter overexpression. Brain Res Mol Brain Res 73:37-49, 1999
59. Murer MG, Dziewczapolski G, Menalled LB, et al: Chronic levodopa is not toxic for remaining dopamine neurons, but instead promotes their recovery, in rats with moderate nigrostriatal lesions. Ann Neurol 43:561-575, 1998
60. Wilson JM, Kish SJ: The vesicular monoamine transporter, in contrast to the dopamine transporter, is not altered by chronic cocaine self-administration in the rat. J Neurosci 16:3507-3510, 1996
61. Innis RB, Marek KL, Sheff K, et al: Effect of treatment with 1-dopa/carbidopa or 1-selegiline on striatal dopamine transporter SPECT imaging with [123I]beta-CIT. Mov Disord 14:436-442, 1999
62. Marek K, Seibyl J, Shoulson I, et al: Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on parkinson disease progression. JAMA 287:1653-1661, 2002
63. Ahlskog JE, Uitti RJ, O'Connor MK, et al: The effect of dopamine agonist therapy on dopamine transporter imaging in parkinson's disease. Mov Disord 14:940-946, 1999
64. Guttman M, Burkholder J, Kish SJ, et al: [11C]RTI-32 PET studies of the dopamine transporter in early dopa-naive parkinson's disease: Implications for the symptomatic threshold. Neurology 48:1578-1583, 1997
65. Nurmi E, Bergman J, Eskola O, et al: Reproducibility and effect of levodopa on dopamine transporter function measurements: A [18F]CFT PET study. J Cereb Blood Flow Metab 20:1604-1609, 2000
66. Chan GL, Holden JE, Stoessl AJ, et al: Reproducibility studies with 11C-DTBZ, a monoamine vesicular transporter inhibitor in healthy human subjects. J Nucl Med 40:283-289, 1999
67. Booij J, Habraken JB, Bergmans P, et al: Imaging of dopamine transporters with iodine-123-FP-CIT SPECT in healthy controls and patients with parkinson's disease. J Nucl Med 39:1879-1884, 1998
68. Seibyl JP, Marek K, Sheff K, et al: Test/retest reproducibility of iodine-123-beta CIT SPECT brain measurement of dopamine transporters in parkinson's patients. J Nucl Med 38:1453-1459, 1997
69. Vingerhoets FJ, Snow BJ, Schulzer M, et al: Reproducibility of fluorine-18-6-fluorodopa positron emission tomography in normal human subjects. J Nucl Med 35:18-24, 1994